Found: 78
Select item for more details and to access through your institution.
Supportive care for patients undergoing immunotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up.
- Published in:
- Case Reports in Oncological Medicine, 2022, p. 1, doi. 10.1155/2022/4162832
- By:
- Publication type:
- Article
Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in Cancer.
- Published in:
- Pharmaceuticals (14248247), 2020, v. 13, n. 11, p. 406, doi. 10.3390/ph13110406
- By:
- Publication type:
- Article
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 4, p. 959, doi. 10.3390/ijms20040959
- By:
- Publication type:
- Article
Patient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 3, p. 1, doi. 10.1007/s00520-024-08373-x
- By:
- Publication type:
- Article
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08220-5
- By:
- Publication type:
- Article
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08224-1
- By:
- Publication type:
- Article
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08223-2
- By:
- Publication type:
- Article
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 12, p. 1, doi. 10.1007/s00520-023-08071-0
- By:
- Publication type:
- Article
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 11, p. 1, doi. 10.1007/s00520-023-08071-0
- By:
- Publication type:
- Article
Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 2, p. 1129, doi. 10.1007/s00520-020-05906-y
- By:
- Publication type:
- Article
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6159, doi. 10.1007/s00520-020-05710-8
- By:
- Publication type:
- Article
MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6175, doi. 10.1007/s00520-020-05709-1
- By:
- Publication type:
- Article
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6145, doi. 10.1007/s00520-020-05708-2
- By:
- Publication type:
- Article
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6129, doi. 10.1007/s00520-020-05707-3
- By:
- Publication type:
- Article
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6119, doi. 10.1007/s00520-020-05706-4
- By:
- Publication type:
- Article
Cancer immunotherapy–related adverse events: causes and challenges.
- Published in:
- Supportive Care in Cancer, 2020, v. 28, n. 12, p. 6111, doi. 10.1007/s00520-020-05705-5
- By:
- Publication type:
- Article
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
- Published in:
- 2015
- By:
- Publication type:
- journal article
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
- Published in:
- Supportive Care in Cancer, 2015, v. 23, n. 8, p. 2231, doi. 10.1007/s00520-014-2564-x
- By:
- Publication type:
- Article
Chemotherapy-Induced Nausea and Vomiting.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.823842
- By:
- Publication type:
- Article
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.743582
- By:
- Publication type:
- Article
Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.676399
- By:
- Publication type:
- Article
The Clinical Problem of Chemotherapy-Induced Nausea and Vomiting.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 8, p. 763
- By:
- Publication type:
- Article
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
- Published in:
- Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.02254
- By:
- Publication type:
- Article
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
- Published in:
- International Journal of Dermatology, 2011, v. 50, n. 2, p. 129, doi. 10.1111/j.1365-4632.2010.04791.x
- By:
- Publication type:
- Article
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 408, doi. 10.3390/cancers15020408
- By:
- Publication type:
- Article
Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3 + , CD8 + , and Immunoscore Are Associated with a Pathological Complete Response.
- Published in:
- Cancers, 2022, v. 14, n. 10, p. 2525, doi. 10.3390/cancers14102525
- By:
- Publication type:
- Article
Repeated use of granisetron in patients receiving cytostatic agents.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Sister Chromatid Exchanges in Lymphocyte Cultures of Patients Previously Treated with Dibromodulcitol.
- Published in:
- Oncology, 1991, v. 48, n. 3, p. 253, doi. 10.1159/000226937
- By:
- Publication type:
- Article
Plasma Melatonin in Patients with Breast Cancer.
- Published in:
- Oncology, 1990, v. 47, n. 5, p. 401, doi. 10.1159/000226857
- By:
- Publication type:
- Article
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 7, p. 2943, doi. 10.1002/cam4.1560
- By:
- Publication type:
- Article
Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.819790
- By:
- Publication type:
- Article
When and How Do I Use Neoadjuvant Chemotherapy for Breast Cancer?
- Published in:
- Current Treatment Options in Oncology, 2014, v. 15, n. 1, p. 86, doi. 10.1007/s11864-013-0266-0
- By:
- Publication type:
- Article
Doxorubicin-paclitaxel.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 1, p. 40, doi. 10.1002/cncr.10914
- By:
- Publication type:
- Article
The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 6, p. 1793, doi. 10.1007/s00520-013-1776-9
- By:
- Publication type:
- Article
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
- Published in:
- 2011
- By:
- Publication type:
- journal article